Orphan Drugs Market by Distribution Channel, Product and Geography - Forecast and Analysis 2023-2027

Published: Mar 2023 Pages: 171 SKU: IRTNTR46586

The orphan drugs market size is estimated to grow at a CAGR of 14.02% between 2022 and 2027. The orphan drugs market size is forecast to increase by USD 170.8 billion. The growth of the market depends on several factors, including robust pipeline and recent drug approvals, the rising incidence of rare diseases, and the availability of incentives for orphan drug development. 

This orphan drugs market report extensively covers market segmentation by distribution channel (hospital pharmacy, specialty pharmacy, retail pharmacy, and others), product (biologics and non-biologics), and geography (North America, Europe, Asia, and Rest of World (ROW). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Orphan Drugs Market During the Forecast Period?

To learn more about this report, View Report Sample

Orphan Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

The rising incidence of rare diseases is notably driving the market growth, although factors such as delays in diagnosis may impede the market growth. Our researchers analyzed the data with 2022 as the base year and the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Orphan Drugs Market Driver

The rising incidence of rare diseases is notably driving market growth. Rare diseases and a subset of non-orphan diseases are specifically treated with orphan drugs. Inherited genetic disorders, uncommon cancers, tropical infectious diseases, and neurodegenerative illnesses are examples of rare diseases. In spite of their low incidence, rare diseases paradoxically affect a sizable portion of the population worldwide. According to the National Institutes of Health (NIH), 400 million people worldwide suffer from rare diseases. One out of every two patients in the US with a rare disease is a child, according to the NIH. Monogenic or single-gene disorders are very common and frequently passed down through the germline.

However, many inherited rare diseases have no diagnostic tools available. There are about 350 rare diseases that affect 80% of all patients with rare diseases. The 350 rare diseases are therefore the subject of extensive research by numerous diagnostic and pharmaceutical companies. These studies have increased public awareness on the use of orphan products, which will fuel the market's expansion. Therefore, the high incidence of rare diseases will increase the requirement for orphan drugs, which, in turn, will drive market growth during the forecast period.

Significant Orphan Drugs Market Trends

Strategic focus on alliances, partnerships, and M&A is an emerging trend in market growth. Strategic alliances and partnerships allow vendors to co-develop and market products, increase their product portfolios, and reach a wider geographic audience. As a result, it is anticipated that the market's vendors will keep looking for strategic opportunities to seize, which will fuel the market's expansion during the forecast period.

In order to deal with impending patent expiration and the requirement to restock the strong pipeline, the market is currently embracing the M&A trend. A concentration on various therapeutics fueled by rising M&A activities and the adoption of cutting-edge, economical manufacturing technologies will pave the way for the development of novel orphan drugs. Furthermore, the market players are using a variety of strategies for productive strategic alliances to overcome the difficulties posed by manufacturing procedures and translational biology. There have been several cross-disciplinary gene therapy collaborations that have been partnership-focused, including those with patient and advocacy groups, small and large biopharmaceutical companies, and data-driven technology companies. Hence, such collaborations will boost the growth of the market during the forecast period. 

Major Orphan Drugs Market Challenge

Delays in diagnosis are major challenges impeding market growth. A precise and timely diagnosis is the initial step to improving care for people with rare diseases. Due to inaccurate, expensive testing, general ignorance, and the asymptomatic nature of many rare diseases, the diagnosis of these conditions has historically been hampered. A delayed diagnosis can postpone the start of an effective course of treatment, which could cause serious, irreversible, and crippling disease to progress. The delayed diagnosis often results in premature deaths and delays in patient care.

Numerous rare diseases can be misdiagnosed and take longer to diagnose because of the asymptomatic nature of many relatively common symptoms. The longer it takes to diagnose a rare disease, the more physician-patient consultations take place, which may make patients and caregivers feel frustrated and scared when the diagnosis is delayed. The average wait time for patients in developing and underdeveloped nations is 5–30 years between the onset of the first symptoms and the official diagnosis of their illness. Only 30% of cases around the world have access to genetic counseling because rare diseases have genetic roots.  Furthermore, the vast majority of patients around the world are initially given a false diagnosis. This results in the use of therapeutic treatments being restricted and causes medical interventions to be based on incorrect diagnoses. Hence, these limitations will negatively impact the global market during the forecast period.

Key Orphan Drugs Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Orphan Drugs Market Customer Landscape

Who are the Major Orphan Drugs Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc. - The company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. The key offerings of the company include orphan drugs such as Humira and Venetoclax.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • Alnylam Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • bluebird bio Inc.
  • Bristol Myers Squibb Co.
  • CSL Ltd.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Johnson and Johnson Services Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Orphan Drugs Market?

The market share growth by the hospital pharmacy segment will be significant during the forecast period. Inpatient medications are prepared, made, stored, and distributed by the hospital pharmacy department. Orphan diseases are rare diseases that require the quickest and easiest care and treatment. In general, the easiest place to meet these needs is a hospital pharmacy.

Get a glance at the market contribution of various segments View the PDF Sample

The hospital pharmacy segment was valued at USD 53.66 billion in 2017 and continued to grow until 2021. This segment has several benefits, including the ability to tailor each patient's dosing schedule. assisting medical professionals in making drug-related decisions and assisting patients in understanding and taking their medications. These uses are helping this market segment grow. Additionally, studies reveal that orphan drugs that were approved in the US, Europe, and Japan had respective market availability rates of 37.8%, 24.6%, and 52.4%. At the 24 tertiary public hospitals, the median availability of 31 orphan drugs was 20.8%. Thus, the hospital pharmacy segment in the market is expected to witness growth during the forecast period.

Which are the Key Regions for the Orphan Drugs Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The market growth in North America is mainly attributed to six driving factors, namely, new drug approvals, growing diagnosis of rare diseases, availability of reimbursement schemes, the high premium price of orphan drugs, the strong presence of key vendors of orphan drugs, and incentives or encouragement from government regulatory agencies and non-profit organizations. Novel drugs have been flooding the US market in North America over the past ten years. To aid in the evaluation and development of products that show promise for the diagnosis and/or treatment of rare diseases, the US FDA established the Office of Orphan Products Development (OOPD). A record number of orphan drugs were approved and introduced in the US in 2022, providing patients with new treatment options. The market in North America is anticipated to experience growth during the forecast period as a result of such a favorable environment for the approval of new drugs.

Another key factor influencing the growth of the market in North America is the increasing prevalence of rare diseases. Due to the development of sophisticated and affordable genetic profiling, the diagnosis rate for rare diseases has been rising in the US and Canada over time. Approximately 7,000 rare diseases affect 25–30 million people in the US today, according to the National Institutes of Health (NIH) and the US Food and Drug Administration, with 250–280 new rare diseases being described each year. Additionally, about 350 well-known rare diseases affect 80% of all patients who receive a diagnosis of a rare disease. Thus, the high prevalence of rare diseases will help propel the market in North America during the forecast period.

The COVID-19 pandemic affected the market in 2020 owing to the demand-supply gap for orphan drugs in North America or the treatment of rare diseases. However, clinical trials conducted by multiple key players for using orphan drugs for the treatment of COVID-19 provided ample opportunities. Moreover, in 2021, with the large-scale vaccination drive, the number of COVID cases was reduced which led to the lifting of the lockdown restrictions and helped the market resume its business activities. This increased the demand for such drugs in the region. Hence, such factors will boost the market in the region during the forecast period.

Segment Overview

The orphan drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Distribution Channel Outlook (USD Billion, 2017 - 2027)
    • Hospital pharmacy
    • Specialty pharmacy
    • Retail pharmacy
    • Others
  • Product Outlook (USD Billion, 2017 - 2027)
    • Biologics
    • Non-biologics
  • Region Outlook (USD Billion, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
      • Others
    • Rest of World
      • Saudi Arabia
      • South Africa
      • Others

Parent Market Analysis

Technavio categorizes the global orphan drugs market within the overall healthcare industry. The parent, the global pharmaceuticals, market covers products and companies engaged in R&D or the production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.

Orphan Drugs Market Scope

Report Coverage

Details

Page number

171

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 14.02%

Market growth 2023-2027

USD 170.8 billion

Market structure

Fragmented

YoY growth 2022-2023(%)

13.24

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Canada, UK, Germany, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, bluebird bio Inc., Bristol Myers Squibb Co., CSL Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Ractigen Therapeutics, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Vertex Pharmaceuticals Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View the PDF sample

What are the Key Data Covered in this Orphan Drugs Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the orphan drugs market between 2023 and 2027
  • Precise estimation of the size of the orphan drugs market size and its contribution to the market in focus on the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of orphan drugs market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global orphan drugs market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global orphan drugs market 2017 - 2021 ($ billion)
    • 4.2 Distributed Channel Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Distributed Channel Segment 2017 - 2021 ($ billion)
    • 4.3 Product Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Product Segment 2017 - 2021 ($ billion)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Distribution Channel

    • 6.1 Market segments
      • Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 6.2 Comparison by Distribution Channel
      • Exhibit 32: Chart on Comparison by Distribution Channel
      • Exhibit 33: Data Table on Comparison by Distribution Channel
    • 6.3 Hospital pharmacy - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
    • 6.4 Specialty pharmacy - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 39: Data Table on Specialty pharmacy - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 40: Chart on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Specialty pharmacy - Year-over-year growth 2022-2027 (%)
    • 6.5 Retail pharmacy - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 43: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 44: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
    • 6.6 Others - Market size and forecast 2022-2027
      • Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 6.7 Market opportunity by Distribution Channel
      • Exhibit 50: Market opportunity by Distribution Channel ($ billion)
      • Exhibit 51: Data Table on Market opportunity by Distribution Channel ($ billion)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 52: Chart on Product - Market share 2022-2027 (%)
      • Exhibit 53: Data Table on Product - Market share 2022-2027 (%)
    • 7.2 Comparison by Product
      • Exhibit 54: Chart on Comparison by Product
      • Exhibit 55: Data Table on Comparison by Product
    • 7.3 Biologics - Market size and forecast 2022-2027
      • Exhibit 56: Chart on Biologics - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 57: Data Table on Biologics - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 58: Chart on Biologics - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
    • 7.4 Non-biologics - Market size and forecast 2022-2027
      • Exhibit 60: Chart on Non-biologics - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 61: Data Table on Non-biologics - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 62: Chart on Non-biologics - Year-over-year growth 2022-2027 (%)
      • Exhibit 63: Data Table on Non-biologics - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Product
      • Exhibit 64: Market opportunity by Product ($ billion)
      • Exhibit 65: Data Table on Market opportunity by Product ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 UK - Market size and forecast 2022-2027
      • Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.9 Canada - Market size and forecast 2022-2027
      • Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.10 China - Market size and forecast 2022-2027
      • Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.11 Germany - Market size and forecast 2022-2027
      • Exhibit 103: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 104: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 105: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 106: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ billion)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 115: AbbVie Inc. - Overview
              • Exhibit 116: AbbVie Inc. - Product / Service
              • Exhibit 117: AbbVie Inc. - Key news
              • Exhibit 118: AbbVie Inc. - Key offerings
            • 12.4 Alnylam Pharmaceuticals Inc.
              • Exhibit 119: Alnylam Pharmaceuticals Inc. - Overview
              • Exhibit 120: Alnylam Pharmaceuticals Inc. - Product / Service
              • Exhibit 121: Alnylam Pharmaceuticals Inc. - Key news
              • Exhibit 122: Alnylam Pharmaceuticals Inc. - Key offerings
            • 12.5 Astellas Pharma Inc.
              • Exhibit 123: Astellas Pharma Inc. - Overview
              • Exhibit 124: Astellas Pharma Inc. - Product / Service
              • Exhibit 125: Astellas Pharma Inc. - Key news
              • Exhibit 126: Astellas Pharma Inc. - Key offerings
            • 12.6 AstraZeneca Plc
              • Exhibit 127: AstraZeneca Plc - Overview
              • Exhibit 128: AstraZeneca Plc - Product / Service
              • Exhibit 129: AstraZeneca Plc - Key news
              • Exhibit 130: AstraZeneca Plc - Key offerings
            • 12.7 bluebird bio Inc.
              • Exhibit 131: bluebird bio Inc. - Overview
              • Exhibit 132: bluebird bio Inc. - Product / Service
              • Exhibit 133: bluebird bio Inc. - Key offerings
            • 12.8 Bristol Myers Squibb Co.
              • Exhibit 134: Bristol Myers Squibb Co. - Overview
              • Exhibit 135: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 136: Bristol Myers Squibb Co. - Key news
              • Exhibit 137: Bristol Myers Squibb Co. - Key offerings
            • 12.9 CSL Ltd.
              • Exhibit 138: CSL Ltd. - Overview
              • Exhibit 139: CSL Ltd. - Business segments
              • Exhibit 140: CSL Ltd. - Key news
              • Exhibit 141: CSL Ltd. - Key offerings
              • Exhibit 142: CSL Ltd. - Segment focus
            • 12.10 F. Hoffmann La Roche Ltd.
              • Exhibit 143: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 144: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 145: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 146: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 147: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.11 Gilead Sciences Inc.
              • Exhibit 148: Gilead Sciences Inc. - Overview
              • Exhibit 149: Gilead Sciences Inc. - Product / Service
              • Exhibit 150: Gilead Sciences Inc. - Key news
              • Exhibit 151: Gilead Sciences Inc. - Key offerings
            • 12.12 GlaxoSmithKline Plc
              • Exhibit 152: GlaxoSmithKline Plc - Overview
              • Exhibit 153: GlaxoSmithKline Plc - Business segments
              • Exhibit 154: GlaxoSmithKline Plc - Key news
              • Exhibit 155: GlaxoSmithKline Plc - Key offerings
              • Exhibit 156: GlaxoSmithKline Plc - Segment focus
            • 12.13 Ipsen Pharma
              • Exhibit 157: Ipsen Pharma - Overview
              • Exhibit 158: Ipsen Pharma - Business segments
              • Exhibit 159: Ipsen Pharma - Key offerings
              • Exhibit 160: Ipsen Pharma - Segment focus
            • 12.14 Johnson and Johnson Services Inc.
              • Exhibit 161: Johnson and Johnson Services Inc. - Overview
              • Exhibit 162: Johnson and Johnson Services Inc. - Business segments
              • Exhibit 163: Johnson and Johnson Services Inc. - Key news
              • Exhibit 164: Johnson and Johnson Services Inc. - Key offerings
              • Exhibit 165: Johnson and Johnson Services Inc. - Segment focus
            • 12.15 Merck and Co. Inc.
              • Exhibit 166: Merck and Co. Inc. - Overview
              • Exhibit 167: Merck and Co. Inc. - Business segments
              • Exhibit 168: Merck and Co. Inc. - Key news
              • Exhibit 169: Merck and Co. Inc. - Key offerings
              • Exhibit 170: Merck and Co. Inc. - Segment focus
            • 12.16 Novartis AG
              • Exhibit 171: Novartis AG - Overview
              • Exhibit 172: Novartis AG - Business segments
              • Exhibit 173: Novartis AG - Key offerings
              • Exhibit 174: Novartis AG - Segment focus
            • 12.17 Ractigen Therapeutics
              • Exhibit 175: Ractigen Therapeutics - Overview
              • Exhibit 176: Ractigen Therapeutics - Product / Service
              • Exhibit 177: Ractigen Therapeutics - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 178: Inclusions checklist
                • Exhibit 179: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 180: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 181: Research methodology
                • Exhibit 182: Validation techniques employed for market sizing
                • Exhibit 183: Information sources
              • 13.5 List of abbreviations
                • Exhibit 184: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              orphan drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis